Between Seroquel, Nexium and Crestor, AstraZeneca investors may have felt over the past few years that the extended fall off the patent cliff would never stop smarting. But the company promises things will turn around if they’ll just hang on.
With cash flow under pressure, AstraZeneca could struggle to live up to CEO Pascal Soriot's commitment to pay a generous dividend "today, tomorrow, and thereafter."
